The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
Open accessAbstract
OBJECTIVE: Type 2 diabetes and obesity are pro-inflammatory states associated with increased risk of cardiovascular disease. Canagliflozin, an SGLT2 inhibitor, demonstrated superiority in lowering HbA1c versus glimepiride with less hypoglycemia and greater weight reduction via loss of fat mass in a 52-week trial of type 2 diabetes patients. This post hoc, exploratory analysis assessed the effects of canagliflozin versus glimepiride on select adipokines, inflammatory biomarkers, and chemokines. METHODS: Changes from baseline to Week 52 in serum leptin, adiponectin, IL-6, TNFα, CRP, PAI-1, VCAM-1, and MCP-1 were measured in a randomly selected subset of type 2 diabetes patients on metformin receiving canagliflozin 300 mg (n = 100) or glimepiride (n = 100) in the overall study. Correlations between change in biomarkers and change in select metabolic and anthropometric variables were assessed. RESULTS: At Week 52, canagliflozin decreased median serum leptin by 25% (95% CI: -34%, -15%) and increased median serum adiponectin by 17% (95% CI: 11%, 23%) compared with glimepiride. There was a 22% reduction in median serum IL-6 (95% CI: -34%, -10%) and a 7% increase in median serum TNFα (95% CI: 1%, 12%) with canagliflozin versus glimepiride. No between-group differences were observed with the other biomarkers. The decrease in serum leptin with canagliflozin was correlated with change in weight (r ≥ 0.3) only; the increase in adiponectin and decrease in IL-6 with canagliflozin occurred independently of changes in HbA1c, weight, or lipids. CONCLUSIONS: These results indicate that canagliflozin may improve adipose tissue function and induce changes in serum leptin, adiponectin, and IL-6 that favorably impact insulin sensitivity and cardiovascular disease risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Derosa, G., Bonaventura, A., Bianchi, L., Romano, D., Fogari, E., D’Angelo, A., & Maffioli, P. (2014) · Diabetic Medicine · doi:10.1111/dme.12499 · Cited by 14
RetractedEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814
Adipose Tissue, Inflammation, and Cardiovascular Disease
Berg, A. H., & Scherer, P. E. (2005) · Circulation Research · doi:10.1161/01.res.0000163635.62927.34 · Cited by 2,113
Association of Hypoadiponectinemia With Coronary Artery Disease in Men
Kumada, M., Kihara, S., Sumitsuji, S., Kawamoto, T., Matsumoto, S., Ouchi, N., Arita, Y., Okamoto, Y., Shimomura, I., Hiraoka, H., et al. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000048856.22331.50 · Cited by 1,420
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Adipokines in health and disease
Fasshauer, M., & Blüher, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.014 · Cited by 1,050
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Yu, J. G., Javorschi, S., Hevener, A. L., Kruszynska, Y. T., Norman, R. A., Sinha, M., & Olefsky, J. M. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2968 · Cited by 725
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Self-citationFerrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
Self-citationAdiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation
Fu, Y., Luo, N., Klein, R. L., & Garvey, W. T. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400373-jlr200 · Cited by 666
Self-citationThe role of leptin/adiponectin ratio in metabolic syndrome and diabetes
López-Jaramillo, P., Gómez-Arbeláez, D., López-López, J., López-López, C., Martínez-Ortega, J., Gómez-Rodríguez, A., & Triana-Cubillos, S. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2013-0053 · Cited by 405
Blüher, M., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.016 · Cited by 399
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 399
Lara-Castro, C., Fu, Y., Chung, B. H., & Garvey, W. T. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32814a645f · Cited by 315
Self-citationTahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 310
Sattar, N., McLaren, J., Kristensen, S. L., Preiss, D., & McMurray, J. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3956-x · Cited by 309
Low Plasma Adiponectin Levels Predict Progression of Coronary Artery Calcification
Maahs, D. M., Ogden, L. G., Kinney, G. L., Wadwa, P., Snell-Bergeon, J. K., Dabelea, D., Hokanson, J. E., Ehrlich, J., Eckel, R. H., & Rewers, M. (2005) · Circulation · doi:10.1161/01.cir.0000155251.03724.a5 · Cited by 294
Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control
Pfützner, A., Marx, N., Lübben, G., Langenfeld, M., Walcher, D., Konrad, T., & Forst, T. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.041 · Cited by 268
Bailey, C. J., Iqbal, N., T'joen, C., & List, J. F. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01659.x · Cited by 167
Self-citationAdiponectin reduces lipid accumulation in macrophage foam cells
Tian, L., Luo, N., Klein, R. L., Chung, B. H., Garvey, W. T., & Fu, Y. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.04.011 · Cited by 150
Self-citationTwo Patterns of Adipokine and Other Biomarker Dynamics in a Long-Term Weight Loss Intervention
Blüher, M., Rudich, A., Klöting, N., Golan, R., Henkin, Y., Rubin, E., Schwarzfuchs, D., Gepner, Y., Stampfer, M. J., Fiedler, M., et al. (2011) · Diabetes Care · doi:10.2337/dc11-1267 · Cited by 136
Clinical endocrinology of human leptin
Gaal, L. V., Wauters, M., Mertens, I. L., Considine, R. V., & Leeuw, I. D. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800792 · Cited by 117
Luo, N., Liu, J., Chung, B. H., Yang, Q., Klein, R. L., Garvey, W. T., & Fu, Y. (2010) · Diabetes · doi:10.2337/db09-1338 · Cited by 114
Self-citationRosenthal, N., Meininger, G. E., Ways, K., Polidori, D., Desai, M. G., Qiu, R., Alba, M., Vercruysse, F., Balis, D. A., Shaw, W. C., et al. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12852 · Cited by 102
Blonde, L., Stenlöf, K., Fung, A., Xie, J., Canovatchel, W. J., & Meininger, G. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1169894 · Cited by 82
Derosa, G., Putignano, P., Bossi, A. C., Bonaventura, A., Querci, F., Franzetti, I., Guazzini, B., Testori, G., Fogari, E., & Maffioli, P. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.051 · Cited by 73
Enhanced adiponectin actions by overexpression of adiponectin receptor 1 in macrophages
Luo, N., Chung, B. H., Wang, X., Klein, R. L., Tang, C., Garvey, W. T., & Fu, Y. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.02.026 · Cited by 48
Self-citationNakamura, I., Oyama, J., Komoda, H., Shiraki, A., Sakamoto, Y., Taguchi, I., Atsushi, H., Komatsu, A., Takeuchi, M., Yamagishi, S., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-15 · Cited by 44
Matsumura, M., Nakatani, Y., Tanka, S., Aoki, C., Sagara, M., Yanagi, K., Suzuki, K., & Aso, Y. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0274-3 · Cited by 41
Petrică, L., Petrica, M., Vlad, A., Jianu, D. C., Gluhovschi, G., Ianculescu, C., Dumitraşcu, V., Giju, S., Gluhovschi, C. A., Bob, F. R., et al. (2009) · Wiener klinische Wochenschrift · doi:10.1007/s00508-009-1279-3 · Cited by 39
Motomura, T., Okamoto, M., Kitamura, T., Yamamoto, H., Otsuki, M., Asanuma, N., Takagi, M., Kurebayashi, S., Hashimoto, K., Sumitani, S., et al. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.992 · Cited by 26
Sam, S., Haffner, S. M., Davidson, M. H., D’Agostino, R. B., Pérez, A., & Mazzone, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1699 · Cited by 15
Kargulewicz, A., Szulińska, M., Kujawska-Łuczak, M., Swora-Cwynar, E., Musialik, K., Grzymisławska, M., Kręgielska-Narożna, M., & Bogdański, P. (2016) · PubMed · Cited by 13
Bhattacharya, S. K., Madan, M., Mahajan, P., et al. (2008) · PubMed · Cited by 6
Cited by
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Demir, S., Nawroth, P. P., Herzig, S., & Ekim Üstünel, B. (2021) · Advanced Science · doi:10.1002/advs.202100275 · Cited by 525
Yanai, H., & Yoshida, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051190 · Cited by 468
Bonnet, F., & Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.005 · Cited by 308
Metadata
- Authors
- Garvey, W. T., Van Gaal, L., Leiter, L. A., Vijapurkar, U., List, J., Cuddihy, R., Ren, J., & Davies, M. J.
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 85
- Pages
- 32-37
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W2790286202
- Cited by
- 261
- References
- 38
- FWCI
- 19.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.